142 related articles for article (PubMed ID: 10673994)
1. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
Iveson TJ; Hickish T; Schmitt C; Van Cutsem E
Eur J Cancer; 1999 Dec; 35(13):1796-804. PubMed ID: 10673994
[TBL] [Abstract][Full Text] [Related]
2. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
Levy-Piedbois C; Durand-Zaleski I; Juhel H; Schmitt C; Bellanger A; Piedbois P
Ann Oncol; 2000 Feb; 11(2):157-61. PubMed ID: 10761749
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.
Cunningham D; Falk S; Jackson D
Br J Cancer; 2002 Jun; 86(11):1677-83. PubMed ID: 12087449
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
[TBL] [Abstract][Full Text] [Related]
8. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Ruiz-Millo O; Albert-Mari A; Sendra-Garcia A; Jimenez-Torres NV
J Oncol Pharm Pract; 2014 Oct; 20(5):341-50. PubMed ID: 24177355
[TBL] [Abstract][Full Text] [Related]
9. Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Hartmann JT; Oechsle K; Jäger E; Reis HE; Haag C; Niederle N; Wilke HJ; Pflüger KH; Batran SA; Büchele T; Hofheinz RD; Kanz L; Bokemeyer C
Anticancer Drugs; 2004 Jun; 15(5):473-7. PubMed ID: 15166621
[TBL] [Abstract][Full Text] [Related]
10. Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Schmitt C; Blijham G; Jolain B; Rougier P; Van Cutsem E
Anticancer Drugs; 1999 Jul; 10(6):617-23. PubMed ID: 10885910
[TBL] [Abstract][Full Text] [Related]
11. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
12. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
[TBL] [Abstract][Full Text] [Related]
13. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Ward S; Kaltenthaler E; Cowan J; Brewer N
Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
[TBL] [Abstract][Full Text] [Related]
14. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
[TBL] [Abstract][Full Text] [Related]
15. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
17. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
Köhne CH; van Cutsem E; Wils J; Bokemeyer C; El-Serafi M; Lutz MP; Lorenz M; Reichardt P; Rückle-Lanz H; Frickhofen N; Fuchs R; Mergenthaler HG; Langenbuch T; Vanhoefer U; Rougier P; Voigtmann R; Müller L; Genicot B; Anak O; Nordlinger B;
J Clin Oncol; 2005 Aug; 23(22):4856-65. PubMed ID: 15939923
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).
Manca A; Asseburg C; Bravo Vergel Y; Seymour MT; Meade A; Stephens R; Parmar M; Sculpher MJ
Value Health; 2012 Jan; 15(1):22-31. PubMed ID: 22264968
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M;
Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]